Screener
Arbutus Biopharma Corporation ABUS Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001447028-26-000021
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accounts payable and accrued liabilities | (985) | 4,545 |
| Change in deferred license revenue | — | (812) |
| Other liabilities | (105) | (104) |
| Net cash used in operating activities | (8,110) | (13,391) |
| INVESTING ACTIVITIES | ||
| Purchase of investments in marketable securities | (13,800) | (34,716) |
| Disposition of investments in marketable securities | 16,000 | 46,065 |
| Net cash provided by investing activities | 2,199 | 11,349 |
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is Arbutus Biopharma Corporation's operating cash flow?
- Arbutus Biopharma Corporation (ABUS) reported operating cash flow of -$8.11M in Q1 2026.
- How has Arbutus Biopharma Corporation's operating cash flow changed year-over-year?
- Arbutus Biopharma Corporation's operating cash flow increased by 39.4% year-over-year, from -$13.39M to -$8.11M.
- What is the long-term trend for Arbutus Biopharma Corporation's operating cash flow?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's operating cash flow has grown at a -12.5% compound annual growth rate (CAGR), from -$67.53M to -$39.64M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Arbutus Biopharma Corporation's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude